The NRA assigned PROMOMED DM a credit rating of "A|ru|"

February 16, 2026, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly and hereinafter referred to as PROMOMED, the "Company", and together with its subsidiaries, the "Group") announces that the National Rating Agency (hereinafter referred to as NRA, the Agency) has assigned a credit rating to the subsidiary LLC "PROMOMED DM" at the "A|ru|" level. The rating outlook is stable.

The Agency noted a comfortable level of EBITDA profitability due to the Group's focus on the production of high-value-added drugs, sufficient debt servicing capacity excluding dividends, as well as PROMOMED's leading market positions, a diversified portfolio of drugs and the Group's long-term experience in the pharmaceutical market.

The rating was also influenced by PROMMED's commitment to the best practices of corporate governance and interaction with the investment community: the Group follows the Shareholder Value Growth Strategy adopted in 2025, and also adheres to discipline in terms of meeting its public operational and financial goals.

Commenting on the pharmaceutical market, the NRA separately emphasized the Group's position of security due to the high barriers to entry into the industry associated with the need for large-scale investments in R&D and manufacturing. At the same time, the market itself is developing dynamically, demonstrating annual growth rates of more than 10%.

The rating agency's press release is published on the website: www.ra-national.ru .

The rating from NRA became the second credit rating for the Group. PROMOMED DM LLC also has a rating from Expert RA at the giA level - with a stable outlook (the last rating action was dated June 23, 2025).
Timofey Solovyov, Director of Economics and Finance at PJSC PROMOMED, commented:

Earlier, PROMOMED received from the Agency an uncredited rating of its ordinary shares at the level of "five stars" - the highest possible rating for public companies.

According to NRA estimates, the fair value of PROMOMED shares is in the range of 708-773 rubles, which reflects the potential growth of the Company's share price by more than 70%[1].

About the Company

PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market.

The company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

For investors

For the media

ir@promomed.pro

pr@promomed.pro


Statement of limitation of liability

This message and the information contained therein are not:

- an offer to purchase any securities,
- an invitation to make offers on the acquisition of any securities,
- part of such an offer or invitation,
- advertising of securities in the Russian Federation or other jurisdictions,
- an offer to purchase medicines,
- advertising of medicines,
- by encouraging or recommending transactions,
- it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page. https://e-disclosure.ru/portal/company.aspx?id=38533 .

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from the results contained or expected in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them. Sources

1. Regarding the closing of trading on the Moscow Stock Exchange on 02/11/2026.